We are monitoring the impact of COVID-19 on North America Hemophilia Management Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 271
Share on
Share on

North America Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (US, Canada and Rest of North America) - Industry Analysis on Size, Share, Growth, Trends, Forecast | 2019 - 2024

Pulished: August, 2019
ID: 271
Pages: 143

North America Hemophilia Management Market Size & Growth (2019 - 2024)

As per the report, the size of the Hemophilia Management Market in North America was worth USD 1.87 billion in 2019 and estimated to be growing at a CAGR of 1.52%, to reach USD 2.02 billion by 2024. Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting.

The demand for hemophilia management in North America is influenced by key factors such as increased disease prevalence; increased use of recombinant drugs and plasma factors such as Factor VIII and IX, and advances in technology. Increasing investment in haemophilia drug research and development is also a major factor in driving market growth. However, the growing use of prophylactic treatment for haemophilia, the discovery of new coagulating factors, technological advancements related to devices, flourishing biotechnology industry, increased awareness among people, increased research and development aimed at detecting curative agents are some other critical factors driving the global market for haemophilia treatment.

Notwithstanding the lack of medication available, strict regulatory approvals and high treatment costs are the key factors that impede the growth of North American Haemophilia Management. In addition, elevated costs related to recombinant products, and serious harmful effects associated with products that are plasma-derived are some other major variables challenging the Haemophilia Management market in North America.

Due to the increasing incidence and seriousness of bleeding disorders, increased use of recombinant drugs, increased demand for prophylaxis treatment, increased capacity for active gene therapy, and the geographic presence of key market players, North America have numerous potential growth opportunities in the global market for haemophilia management during the forecast period. Promising final-stage pipeline drugs include long-acting substitute therapies and non-factor therapies that would be approved throughout the forecast period, generating more potential for the haemophilia management market. Also adding to this regional market is growing R&D investments in haemophilia products and advancing medical knowledge and scientific research.

This research report segmented and sub-segmented into the following categories:

  • By Type: Hemophilia A, Hemophilia B
  • By Drug: Octocogalfa, Nonacogalfa, Desmopressin and Other Drugs
  • By Country: US, Canada and Rest of North America

Regionally, North America is the largest market for hemophilia management accounting for approximately XX%. In North America, the United States is the largest market for hemophilia management due to high government support and the increasing number of patients suffering from hemophilia. Canada is estimated to be the fastest-growing region due to high growth potential due to the increasing usage of available medication.

Key players in the North America Hemophilia Management Market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB.

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                         

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                                6.1 Introduction                              

                                6.2 United States                            

                                6.3 Canada                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                            

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Hemophilia Management Market By Region, From 2019-2024 (USD Million)           
  2. North America Hemophilia Management Market By Type, From 2019-2024 (USD Million)         
  3. North America Hemophilia-A Market By Region, From 2019-2024 (USD Million)                                                  
  4. North America Hemophilia-B Market By Region, From 2019-2024 (USD Million)                                                  
  5. North America Hemophilia Management Market By Drug, From 2019-2024 (USD Million)
  6. North America Octocogalfa Market By Region, From 2019-2024 (USD Million)                                                      
  7. North America Nonacogalfa Market By Region, From 2019-2024 (USD Million)                                                     
  8. North America Desmopressin Market By Region, From 2019-2024 (USD Million)                                                 
  9. North America Other drugs Market By Region, From 2019-2024 (USD Million)                                                      
  10. United States Hemophilia Management Market By Type, From 2019-2024 (USD Million)                 
  11. United States Hemophilia Management Market By Drug, From 2019-2024 (USD Million) 
  12. Canada Hemophilia Management Market By Type, From 2019-2024 (USD Million)
  13. Canada Hemophilia Management Market By Drug, From 2019-2024 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample